Showing 7421-7430 of 9461 results for "".
- GLODERM Announces CeraVe Access Grant Recipientshttps://practicaldermatology.com/news/gloderm-announces-access-grant-recipients/2462970/Five dermatologists working in low-resource settings around the world have been awarded $20,000 each as part of the International Alliance for Global Health Dermatology (GLODERM) Mentorship Programme, which aims to increase access to dermatological care in under-served communities. The new GLODER
- Atopic Dermatitis Not Linked with Increased Risk for Venous Thromboembolismhttps://practicaldermatology.com/news/atopic-dermatitis-not-linked-increased-risk-venous-thromboembolism/2462969/A recent retrospective cohort study published in the latest issue of the Journal of the American Academy of Dermatology showed that venous thromboembolism (VTE) risk among patients with atopic dermatitis (AD) was lower than that of other immune-mediated inflammatory diseases (IMIDs).
- FDA Approves New Humira Biosimilar for Multiple Inflammatory Conditionshttps://practicaldermatology.com/news/fda-approves-new-adalimumab-adbm-formulation-multiple-inflammatory-conditions/2462933/Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). According to a press release from the company, the approval enables an expansion of treatment options for chronic inflammatory diseases. This f
- LaserAway Aesthetic Dermatology Chain Welcomes Kelly Lohr as New Customer Officerhttps://practicaldermatology.com/news/laseraway-aesthetic-dermatology-chain-welcomes-kelly-lohr-new-customer-officer/2462909/LaserAway, a prominent aesthetic dermatology chain, has welcomed Kelly Lohr as its inaugural Chief Customer Officer, signaling a move into the health and beauty space, according to a press release from the company. With LaserAway's presence in 145 locations and experiencing significant de
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t
- FDA Accepts sNDA for Dermavant's Tapinarof Cream, 1%https://practicaldermatology.com/news/tapinarof-1-cream-progresses-toward-approval-pediatric-eczema/2462895/The U.S. Food and Drug Administration (FDA) has accepted Dermavant's Supplemental New Drug Application (sNDA) for tapinarof cream, 1% (VTAMA®), for the treatment of atopic dermatitis in (AD), according to a news release from the manufacturer. The FDA assigned a Prescription Drug User Fee
- Abrocitinib Cost-Effective Compared to Standard of Care for Atopic Dermatitis Treatment: Studyhttps://practicaldermatology.com/news/abrocitinib-cost-effective-compared-standard-care-atopic-dermatitis-treatment-japan/2462838/New research from a study of Japanese patients suggests that abrocitinib showed superior efficacy and safety compared to the standard of care (SoC). Recent findings from the JAK-1 Atopic Dermatitis Efficacy and Safety (JADE) program's Phase 3 trials have unveiled promising insights into th
- Oral and Topical Minoxidil for Male Androgenetic Alopecia Show Similar Efficacy: Analysishttps://practicaldermatology.com/news/oral-and-topical-minoxidil-male-androgenetic-alopecia-similar-efficacy-analysis/2462791/Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male androgenetic alopecia (AGA). The authors conducted the double-blind, placebo-controlled randomized clinical trial in Brazil aiming to evalua
- Top Non-cosmetic Laser Indications Vary by Laser Typehttps://practicaldermatology.com/news/top-non-cosmetic-laser-indications-vary-laser-type/2462734/Treatment of psoriasis, vascular lesions, and hypertrophic disorders were the most common non-cosmetic indications for dermatologic use of excimer, vascular, and ablative lasers, respectively, based on data from more than 55,000 individuals. Non-cosmetic laser therapy in dermatology has e
- Micro-Coring Could Offer Nonsurgical Option for Moderate to Severe Rhytidshttps://practicaldermatology.com/news/micro-coring-offers-nonsurgical-option-moderate-severe-rhytids/2462726/A dermal micro-coring device improved the appearance of moderate-to-severe rhytids on the cheek and lower face after two treatments, according to data from a new study presented at the American Society for Laser Medicine and Surgery 43rd Annual Conference on Energy-based Medicine and S